PRMT7

Summary

PRMT7 (protein arginine methyltransferase 7, HGNC:25557) is a protein-coding gene on chromosome 16q22.1, encoding Protein arginine N-methyltransferase 7 (Q9NVM4). Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA.

This gene encodes a member of the protein arginine N-methyltransferase family of proteins. The encoded enzyme transfers single methyl groups to arginine residues to generate monomethylarginines on histone proteins as well as other protein substrates. This enzyme plays a role in a wide range of biological processes, including neuronal differentiation, male germ line imprinting, small nuclear ribonucleoprotein biogenesis, and regulation of the Wnt signaling pathway. Mutations in this gene underlie multiple related syndromes in human patients characterized by intellectual disability, short stature and other features. The encoded protein may promote breast cancer cell invasion and metastasis in human patients.

Source: NCBI Gene 54496 — RefSeq curated summary.

At a glance

• Gene–disease (curated): short stature-brachydactyly-obesity-global developmental delay syndrome (Strong, GenCC)
• GWAS associations: 13
• Clinical variants (ClinVar): 361 total — 21 pathogenic, 20 likely-pathogenic
• Phenotypes (HPO): 89
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_019023

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25557
Approved symbol	PRMT7
Name	protein arginine methyltransferase 7
Location	16q22.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10640, KIAA1933
Ensembl gene	ENSG00000132600
Ensembl biotype	protein_coding
OMIM	610087
Entrez	54496

Gene structure

Transcript identifiers

Ensembl transcripts: 84 — 42 protein_coding, 19 nonsense_mediated_decay, 13 retained_intron, 10 protein_coding_CDS_not_defined

ENST00000339507, ENST00000441236, ENST00000449359, ENST00000561806, ENST00000562050, ENST00000562381, ENST00000562456, ENST00000563443, ENST00000563520, ENST00000563562, ENST00000563608, ENST00000564050, ENST00000564441, ENST00000565356, ENST00000565745, ENST00000565761, ENST00000565983, ENST00000566341, ENST00000566430, ENST00000566687, ENST00000566708, ENST00000567542, ENST00000568463, ENST00000568975, ENST00000569047, ENST00000569571, ENST00000675132, ENST00000685109, ENST00000685141, ENST00000686053, ENST00000686346, ENST00000686904, ENST00000687444, ENST00000687558, ENST00000687654, ENST00000688470, ENST00000688969, ENST00000689486, ENST00000689637, ENST00000690311, ENST00000690432, ENST00000690932, ENST00000691663, ENST00000691804, ENST00000691833, ENST00000691961, ENST00000692283, ENST00000692621, ENST00000692632, ENST00000692760, ENST00000692867, ENST00000692966, ENST00000693200, ENST00000693309, ENST00000693670, ENST00000897111, ENST00000897112, ENST00000897113, ENST00000897114, ENST00000897115, ENST00000897116, ENST00000897117, ENST00000897118, ENST00000926970, ENST00000926971, ENST00000926972, ENST00000926973, ENST00000926974, ENST00000926975, ENST00000926976, ENST00000926977, ENST00000926978, ENST00000926979, ENST00000926980, ENST00000926981, ENST00000950163, ENST00000950164, ENST00000950165, ENST00000950166, ENST00000950167, ENST00000950168, ENST00000950169, ENST00000950170, ENST00000950171

RefSeq mRNA: 10 — MANE Select: NM_019023 NM_001184824, NM_001290018, NM_001351143, NM_001351144, NM_001378018, NM_001378020, NM_001378021, NM_001378022, NM_001378023, NM_019023

CCDS: CCDS10866, CCDS54033, CCDS92184, CCDS92187

Canonical transcript exons

ENST00000441236 — 19 exons

Exon	Start	End
ENSE00001111558	68348342	68348431
ENSE00001516553	68312042	68312176
ENSE00003458240	68329066	68329174
ENSE00003471759	68339788	68339968
ENSE00003518415	68353492	68353566
ENSE00003522691	68339322	68339563
ENSE00003534990	68321426	68321462
ENSE00003547378	68337459	68337571
ENSE00003550788	68356701	68356797
ENSE00003563876	68355723	68355883
ENSE00003571121	68346145	68346280
ENSE00003595568	68352248	68352409
ENSE00003596598	68347211	68347294
ENSE00003597640	68347631	68347678
ENSE00003614857	68345675	68345802
ENSE00003679541	68315897	68316074
ENSE00003692905	68324683	68324832
ENSE00003751779	68357054	68358584
ENSE00003900147	68311019	68311099

Expression profiles

Bgee: expression breadth ubiquitous, 186 present calls, max score 97.50.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.8410 / max 160.4231, expressed in 1798 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
154736	17.5492	1794
154739	0.8597	136
154737	0.2470	124
154738	0.1852	89

Top tissues by expression

274 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	97.50	gold quality
cerebellar hemisphere	UBERON:0002245	97.24	gold quality
cerebellar cortex	UBERON:0002129	96.98	gold quality
right frontal lobe	UBERON:0002810	94.50	gold quality
right uterine tube	UBERON:0001302	94.38	gold quality
apex of heart	UBERON:0002098	93.70	gold quality
cerebellum	UBERON:0002037	93.67	gold quality
hindlimb stylopod muscle	UBERON:0004252	93.46	gold quality
tibial nerve	UBERON:0001323	93.22	gold quality
sural nerve	UBERON:0015488	93.09	gold quality
ventricular zone	UBERON:0003053	93.08	gold quality
right ovary	UBERON:0002118	92.96	gold quality
left ovary	UBERON:0002119	92.84	gold quality
ganglionic eminence	UBERON:0004023	92.75	gold quality
adenohypophysis	UBERON:0002196	92.64	gold quality
body of uterus	UBERON:0009853	92.27	gold quality
right adrenal gland	UBERON:0001233	92.24	gold quality
right adrenal gland cortex	UBERON:0035827	92.00	gold quality
gastrocnemius	UBERON:0001388	91.94	gold quality
cortical plate	UBERON:0005343	91.87	gold quality
muscle of leg	UBERON:0001383	91.86	gold quality
anterior cingulate cortex	UBERON:0009835	91.86	gold quality
left adrenal gland cortex	UBERON:0035825	91.79	gold quality
muscle layer of sigmoid colon	UBERON:0035805	91.77	gold quality
cingulate cortex	UBERON:0003027	91.70	gold quality
left adrenal gland	UBERON:0001234	91.57	gold quality
right lobe of thyroid gland	UBERON:0001119	91.32	gold quality
endocervix	UBERON:0000458	91.29	gold quality
right lobe of liver	UBERON:0001114	91.24	gold quality
colonic epithelium	UBERON:0000397	91.18	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.10
E-MTAB-7303	no	460.92

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTCFL, KMT2B, TCF3

Literature-anchored findings (GeneRIF, showing 24)

• both domains are required for functionality (PMID:15044439)
• PRMT7 (like PRMT5) is a Type II methyltransferase capable of producing symmetric dimethylarginine modifications in proteins. (PMID:15494416)
• that in human cells, PRMT5 and PRMT7 are required for Sm protein sDMA modification, and that Sm protein symmetric dimethylarginine modification is required for snRNP biogenesis in human cells. (PMID:17709427)
• Here the authors report that H3R2 is also symmetrically dimethylated (H3R2me2s) by PRMT5 and PRMT7 and present in euchromatic regions. (PMID:22231400)
• Human protein arginine methyltransferase 7 (PRMT7) is a type III enzyme forming omega-NG-monomethylated arginine residues. (PMID:22241471)
• reducing expression of individual PRMT7 target DNA repair genes showed that only the catalytic subunit of DNA polymerase, POLD1, was able to resensitize PRMT7 knock-down cells to DNA-damaging agents. (PMID:22761421)
• results define PRMT7 as an inducer of breast cancer metastasis and present the opportunity for applying PRMT7-targeted therapeutics to treat highly invasive breast cancers (PMID:25136067)
• Data indicate that two acidic residues within the double E loop, Asp-147 and Glu-149, confer specificity to protein arginine methyltransferase 7 (PRMT7. (PMID:25294873)
• Upregulation of PRMT7 in breast cancer may have a significant role in promoting cell invasion through the regulation of MMP9. (PMID:25605249)
• Loss of PRMT7 causes decreases in arginine methylation throughout the proteome.Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly. (PMID:27718516)
• The authors showed that ASS1 mutations linked to type I citrullinemia disrupt the ASS1-PRMT7 interaction, which might explain the molecular pathogenesis of the disease. (PMID:28587924)
• These kinetic studies suggest a biochemical explanation for the interplay between PRMT5- and PRMT7-mediated methylation of the same substrate at different residues and also suggest a general model for regulation of PRMTs. (PMID:28874563)
• Our findings expand the clinical and molecular spectrum of homozygous PRMT7 mutations, associated to the SBIDDS syndrome, showing a possible correlation between the type of mutation and the severity of the phenotype. (PMID:28902392)
• Our patients provide additional clinical and pathological data and expand the phenotypic manifestations associated with PRMT7 homozygote/compound heterozygote mutations to include brain calcifications and delayed myelination, and congenital orbital tumor. (PMID:30513135)
• PRMT7 promotes the growth of renal cell carcinoma through modulating the beta-catenin/C-MYC axis. (PMID:31926310)
• Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response. (PMID:32409666)
• Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth. (PMID:33782401)
• The role of protein arginine methyltransferase 7 in human developmentally arrested embryos cultured in vitro. (PMID:34041522)
• Arginine monomethylation by PRMT7 controls MAVS-mediated antiviral innate immunity. (PMID:34171297)
• An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression. (PMID:35264579)
• The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD. (PMID:35288557)
• Short stature in PRMT7 Mutations: first evidence of response to growth hormone treatment. (PMID:36348013)
• Biallelic PRMT7 pathogenic variants are associated with a recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities. (PMID:36399134)
• The exquisite specificity of human protein arginine methyltransferase 7 (PRMT7) toward Arg-X-Arg sites. (PMID:37216364)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	prmt7	ENSDARG00000051902
mus_musculus	Prmt7	ENSMUSG00000060098
rattus_norvegicus	Prmt7	ENSRNOG00000000258
drosophila_melanogaster	Art7	FBGN0034817
caenorhabditis_elegans	prmt-7	WBGENE00012298

Paralogs (7): PRMT8 (ENSG00000111218), PRMT1 (ENSG00000126457), CARM1 (ENSG00000142453), PRMT2 (ENSG00000160310), PRMT9 (ENSG00000164169), PRMT3 (ENSG00000185238), PRMT6 (ENSG00000198890)

Protein

Protein identifiers

Protein arginine N-methyltransferase 7 — Q9NVM4 (reviewed: Q9NVM4)

Alternative names: Histone-arginine N-methyltransferase PRMT7, [Myelin basic protein]-arginine N-methyltransferase PRMT7

All UniProt accessions (20): Q9NVM4, A0A6Q8PFP4, A0A8I5KPP4, A0A8I5KPT4, A0A8I5KQA6, A0A8I5KRA7, A0A8I5KRU8, A0A8I5KRV0, A0A8I5KRW2, A0A8I5KWG5, A0A8I5KXS9, A0A8I5KYD6, A0A8I5KZ05, A0A8I5KZ92, A0A8I5QKQ0, A0A8I5QKZ3, H3BNC0, H3BPZ8, H3BRD3, H3BSS9

UniProt curated annotations — full annotation on UniProt →

Function. Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles. Specifically mediates the symmetric dimethylation of histone H4 ‘Arg-3’ to form H4R3me2s. Plays a role in gene imprinting by being recruited by CTCFL at the H19 imprinted control region (ICR) and methylating histone H4 to form H4R3me2s, possibly leading to recruit DNA methyltransferases at these sites. May also play a role in embryonic stem cell (ESC) pluripotency. Also able to mediate the arginine methylation of histone H2A and myelin basic protein (MBP) in vitro; the relevance of such results is however unclear in vivo.

Subunit / interactions. Homodimer and heterodimer. Interacts with CTCFL. Interacts with PRMT5 and SNRPD3.

Subcellular location. Cytoplasm. Cytosol. Nucleus.

Disease relevance. Short stature, brachydactyly, impaired intellectual developmental, and seizures (SBIDDS) [MIM:617157] An autosomal recessive disease characterized by developmental delay, learning disabilities, mild intellectual disability, delayed speech, and skeletal abnormalities. Skeletal features include short stature, brachydactyly, and short metacarpals and metatarsals. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. May be involved in etoposide-induced cytotoxicity, a chemotherapeutic agent frequently used for testicular cancer and small-cell lung cancer that can cause cytotoxicity in the treatment of other cancers. Down-regulation confers increased sensitivity to the Top1 inhibitor camptothecin (CPT).

Similarity. Belongs to the class I-like SAM-binding methyltransferase superfamily. Protein arginine N-methyltransferase family. PRMT7 subfamily.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9NVM4-1	1	yes
Q9NVM4-2	2
Q9NVM4-3	3
Q9NVM4-4	4

RefSeq proteins (10): NP_001171753, NP_001276947, NP_001338072, NP_001338073, NP_001364947, NP_001364949, NP_001364950, NP_001364951, NP_001364952, NP_061896* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR014644	MeTrfase_PRMT7	Family
IPR025799	Arg_MeTrfase	Family
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily
IPR055135	PRMT_dom	Domain

Pfam: PF06325, PF22528

Enzyme classification (BRENDA):

• EC 2.1.1.321 — type III protein arginine methyltransferase (BRENDA: 7 organisms, 78 substrates, 27 inhibitors, 15 Km, 2 kcat entries)

Substrate kinetics (BRENDA)

10 substrates with measured Km, best-characterized 10. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ACTEYL-KKDGKKRKRSRKESY-AMIDE	0.0006–0.017	2
ACTEYL-KKGGRGRGGKKY-AMIDE	0.0007–0.0062	2
ACTEYL-KKGGRGRKGKKY-AMIDE	0.0005–0.0024	2
ACTEYL-KKGGRKRGGKKY-AMIDE	0.0006–0.0069	2
ACTEYL-KKGKRGRGGKKY-AMIDE	0.0006–0.0033	2
ACTEYL-KKGGRERGGKKY-AMIDE	0.0028	1
ACTEYL-KKGGRGGGGKKY-AMIDE	0.0014	1
S-ADENOSYL-L-HOMOCYSTEINE	0.0016	1
[HEAT SHOCK PROTEIN A8]-L-ARGININE469	0.0106	1
[HISTONE H2B PEPTIDE 23-37]-L-ARGININE	0.0069	1

Catalyzed reactions (Rhea), 1 shown:

• L-arginyl-[protein] + S-adenosyl-L-methionine = N(omega)-methyl-L-arginyl-[protein] + S-adenosyl-L-homocysteine + H(+) (RHEA:48100)

UniProt features (18 total): splice variant 5, sequence conflict 4, sequence variant 3, domain 2, active site 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NVM4-F1	93.19	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 144; 153

Post-translational modifications (1): 32

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-3214858	RMTs methylate histone arginines
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-4839726	Chromatin organization

MSigDB gene sets: 346 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE45365_NK_CELL_VS_BCELL_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, chr16q22, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_PROTEIN_RNA_COMPLEX_ORGANIZATION, GOBP_RNA_SPLICING, GOBP_GENOMIC_IMPRINTING, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOBP_CHROMATIN_REMODELING, GOBP_METHYLATION, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, CUI_TCF21_TARGETS_2_UP, GOBP_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION

GO Biological Process (9): spliceosomal snRNP assembly (GO:0000387), chromatin remodeling (GO:0006338), regulation of DNA-templated transcription (GO:0006355), peptidyl-arginine methylation (GO:0018216), genomic imprinting (GO:0071514), chromatin organization (GO:0006325), protein methylation (GO:0006479), cell differentiation (GO:0030154), methylation (GO:0032259)

GO Molecular Function (13): S-adenosylmethionine-dependent methyltransferase activity (GO:0008757), protein-arginine N-methyltransferase activity (GO:0016274), protein-arginine omega-N monomethyltransferase activity (GO:0035241), protein-arginine omega-N symmetric methyltransferase activity (GO:0035243), histone methyltransferase activity (GO:0042054), histone binding (GO:0042393), ribonucleoprotein complex binding (GO:0043021), histone H4R3 methyltransferase activity (GO:0044020), histone H4 methyltransferase activity (GO:0140939), protein binding (GO:0005515), methyltransferase activity (GO:0008168), protein methyltransferase activity (GO:0008276), transferase activity (GO:0016740)

GO Cellular Component (5): fibrillar center (GO:0001650), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Chromatin modifying enzymes	1
Chromatin organization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
protein-arginine N-methyltransferase activity	3
methyltransferase activity	2
protein methyltransferase activity	2
mRNA splicing, via spliceosome	1
protein-RNA complex assembly	1
chromatin organization	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
protein methylation	1
peptidyl-arginine modification	1
germ cell development	1
epigenetic programming of gene expression	1
cellular component organization	1
protein alkylation	1
macromolecule methylation	1
cellular developmental process	1
metabolic process	1
arginine N-methyltransferase activity	1
histone modifying activity	1
protein binding	1
protein-containing complex binding	1
histone H4 methyltransferase activity	1
histone methyltransferase activity	1
binding	1
transferase activity, transferring one-carbon groups	1
catalytic activity, acting on a protein	1
catalytic activity	1
nucleolus	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1922 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRMT7	PRMT5	O14744	963
PRMT7	CTCFL	Q8NI51	857
PRMT7	H4C7	Q99525	709
PRMT7	H4C16	P02304	691
PRMT7	FBL	P22087	680
PRMT7	SNRPD3	P43331	665
PRMT7	PRMT8	Q9NR22	663
PRMT7	WDR77	Q9BQA1	629
PRMT7	SMYD3	Q9H7B4	611
PRMT7	SF3B2	Q13435	570
PRMT7	PRMT1	Q99873	565
PRMT7	YY1	P25490	506
PRMT7	DNMT1	P26358	496
PRMT7	PRMT3	O60678	481
PRMT7	SMURF1	Q9HCE7	477

IntAct

45 interactions, top by confidence:

A	B	Type	Score
EIF2S1	EIF2S3	psi-mi:“MI:0914”(association)	0.820
EIF2S2	EIF2S1	psi-mi:“MI:0914”(association)	0.810
EIF2S1	PRMT7	psi-mi:“MI:0915”(physical association)	0.670
PRMT7	ASS1	psi-mi:“MI:0915”(physical association)	0.640
PRMT7	ASS1	psi-mi:“MI:0407”(direct interaction)	0.640
PRMT7	ASS1	psi-mi:“MI:0403”(colocalization)	0.640
ZNF438	PRMT7	psi-mi:“MI:0915”(physical association)	0.560
NFKBID	PRMT7	psi-mi:“MI:0915”(physical association)	0.560
POT1	PRMT7	psi-mi:“MI:0915”(physical association)	0.370
ECE1	PRMT7	psi-mi:“MI:0915”(physical association)	0.370
PRMT7	H3-5	psi-mi:“MI:0915”(physical association)	0.370
PRMT7	MNDA	psi-mi:“MI:0915”(physical association)	0.370
PRMT7	ZBTB24	psi-mi:“MI:0915”(physical association)	0.370
PRMT7	SSR3	psi-mi:“MI:0914”(association)	0.350
PIK3CG	UTRN	psi-mi:“MI:0914”(association)	0.350
rl10_rl10l_human	FBN2	psi-mi:“MI:0914”(association)	0.350
TAFA3	FUOM	psi-mi:“MI:0914”(association)	0.350
C1QTNF8	VWA8	psi-mi:“MI:0914”(association)	0.350
EIF2S2	TOR1B	psi-mi:“MI:0914”(association)	0.350
SMAD7	PSMG1	psi-mi:“MI:0914”(association)	0.350
THAP8	SNAP29	psi-mi:“MI:0914”(association)	0.350
EZR	EEF2K	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (69): PRMT7 (Affinity Capture-MS), PRMT7 (Affinity Capture-MS), PRMT7 (Co-fractionation), SSR3 (Affinity Capture-MS), REPS2 (Affinity Capture-MS), GANAB (Affinity Capture-MS), ICE1 (Affinity Capture-MS), PRMT7 (Affinity Capture-MS), PRMT7 (Affinity Capture-MS), PRMT7 (Affinity Capture-MS), PRMT7 (Affinity Capture-MS), PRMT7 (Affinity Capture-MS), PRMT7 (Affinity Capture-MS), PRMT7 (Negative Genetic), PRMT7 (Proximity Label-MS)

ESM2 similar proteins: A0A1W2PQ27, A0A1W2PQ64, A0A1W2PQC6, A0A1W2PQD8, A0A1W2PQJ5, A0A1W2PR75, A2AV36, A4QN59, A6QQV6, D4A1F2, F1RA39, G5E8F4, J9SQF3, O00142, O42868, O55239, O95050, O95932, O97972, P0CR76, P0CR77, P10938, P40261, P40936, P53538, Q01841, Q22453, Q32LP9, Q4R7D0, Q566Y1, Q5M9G7, Q5RFR7, Q5U4E8, Q5XG58, Q62160, Q6C195, Q6CQ61, Q6DE00, Q6FMU7, Q6PCI6

Diamond homologs: A0A3Q0KHE7, A0A411EW25, A0JMU5, A2AV36, A2Y953, A2YPT7, A2Z0C0, A3KPF2, A6QQV6, A8IEF3, B0JYW5, B0W3L6, B3DLB3, B3M1E1, B3P4N5, B4GZ20, B4HJC0, B4JXV2, B4KA23, B4LVS8, B4MNL1, B4NKI9, B4PVH6, B4QVW6, D9IVE5, O13648, O60678, O70467, O82210, P38074, P55345, Q08A71, Q0J2C6, Q174R2, Q28F07, Q29B63, Q3U3W5, Q4AE70, Q54EF2, Q54HI0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

361 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	21
Likely pathogenic	20
Uncertain significance	152
Likely benign	104
Benign	19

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1098280	NM_019023.5(PRMT7):c.622del (p.Gln208fs)	Pathogenic
1119980	NM_019023.5(PRMT7):c.1097G>A (p.Cys366Tyr)	Pathogenic
1323497	NM_019023.5(PRMT7):c.98C>A (p.Ser33Ter)	Pathogenic
2577129	NM_019023.5(PRMT7):c.967C>T (p.Gln323Ter)	Pathogenic
266020	NM_019023.5(PRMT7):c.1276-1G>A	Pathogenic
2754073	NM_019023.5(PRMT7):c.847del (p.Asp283fs)	Pathogenic
3069131	NM_019023.5(PRMT7):c.1168C>T (p.Arg390Ter)	Pathogenic
3236051	NM_019023.5(PRMT7):c.1173C>G (p.Tyr391Ter)	Pathogenic
3254663	NM_019023.5(PRMT7):c.1678del (p.Glu560fs)	Pathogenic
3366822	NM_019023.5(PRMT7):c.477T>A (p.Tyr159Ter)	Pathogenic
3651536	NM_019023.5(PRMT7):c.194del (p.Lys65fs)	Pathogenic
3775502	NM_019023.5(PRMT7):c.82C>T (p.Gln28Ter)	Pathogenic
3893271	NM_019023.5(PRMT7):c.1105C>T (p.Gln369Ter)	Pathogenic
427216	NC_000016.9:g.68345747_68361056del	Pathogenic
4685006	NM_019023.5(PRMT7):c.2008del (p.Tyr670fs)	Pathogenic
522559	NM_019023.5(PRMT7):c.431_432del (p.Glu144fs)	Pathogenic
522593	NM_019023.5(PRMT7):c.1239_1246dup (p.Val416fs)	Pathogenic
523434	NM_019023.5(PRMT7):c.1713C>A (p.Cys571Ter)	Pathogenic
951784	NM_019023.5(PRMT7):c.77del (p.Tyr26fs)	Pathogenic
984615	NM_019023.5(PRMT7):c.148C>T (p.Gln50Ter)	Pathogenic
986005	NM_019023.5(PRMT7):c.1402C>T (p.Gln468Ter)	Pathogenic
1098281	NM_019023.5(PRMT7):c.927G>T (p.Gln309His)	Likely pathogenic
1305249	NM_019023.5(PRMT7):c.391+5G>C	Likely pathogenic
1332826	NM_019023.5(PRMT7):c.457dup (p.Glu153fs)	Likely pathogenic
1334191	NM_019023.5(PRMT7):c.347T>A (p.Ile116Asn)	Likely pathogenic
1693267	NM_019023.5(PRMT7):c.1220G>A (p.Cys407Tyr)	Likely pathogenic
1693268	NM_019023.5(PRMT7):c.1323+2T>G	Likely pathogenic
1878579	NM_019023.5(PRMT7):c.1335_1338dup (p.His447Ter)	Likely pathogenic
266022	NM_019023.5(PRMT7):c.95G>C (p.Arg32Thr)	Likely pathogenic
266023	NM_019023.5(PRMT7):c.1159A>G (p.Arg387Gly)	Likely pathogenic

SpliceAI

3801 predictions. Top by Δscore:

Variant	Effect	Δscore
16:68321463:G:GG	donor_gain	1.0000
16:68337457:A:AG	acceptor_gain	1.0000
16:68337457:AGAG:A	acceptor_gain	1.0000
16:68337458:G:GG	acceptor_gain	1.0000
16:68337458:GAGG:G	acceptor_gain	1.0000
16:68345667:C:CA	acceptor_gain	1.0000
16:68345670:TTCA:T	acceptor_loss	1.0000
16:68345672:CAGTG:C	acceptor_loss	1.0000
16:68345673:A:AG	acceptor_gain	1.0000
16:68345673:AGT:A	acceptor_gain	1.0000
16:68345673:AGTG:A	acceptor_gain	1.0000
16:68345674:G:GA	acceptor_gain	1.0000
16:68345674:GT:G	acceptor_gain	1.0000
16:68345674:GTG:G	acceptor_gain	1.0000
16:68345674:GTGG:G	acceptor_gain	1.0000
16:68345674:GTGGC:G	acceptor_gain	1.0000
16:68345675:T:TA	acceptor_gain	1.0000
16:68345799:CCAG:C	donor_loss	1.0000
16:68345800:CAG:C	donor_loss	1.0000
16:68345801:AG:A	donor_loss	1.0000
16:68345802:GG:G	donor_loss	1.0000
16:68345803:G:A	donor_loss	1.0000
16:68345804:T:A	donor_loss	1.0000
16:68346131:A:AG	acceptor_gain	1.0000
16:68346132:T:G	acceptor_gain	1.0000
16:68346137:T:A	acceptor_gain	1.0000
16:68346138:G:A	acceptor_gain	1.0000
16:68346140:CCTA:C	acceptor_loss	1.0000
16:68346141:CTAG:C	acceptor_loss	1.0000
16:68346143:A:AG	acceptor_gain	1.0000

AlphaMissense

4591 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:68321461:G:C	R44T	0.999
16:68321462:A:C	R44S	0.999
16:68321462:A:T	R44S	0.999
16:68337498:A:T	E144V	0.999
16:68345687:T:A	W314R	0.999
16:68345687:T:C	W314R	0.999
16:68321443:T:C	M38T	0.998
16:68321452:A:T	D41V	0.998
16:68321461:G:T	R44I	0.998
16:68324753:T:A	V68D	0.998
16:68324756:T:C	L69P	0.998
16:68324777:G:A	G76E	0.998
16:68337507:A:T	D147V	0.998
16:68339885:T:A	W282R	0.998
16:68339885:T:C	W282R	0.998
16:68345675:T:A	W310R	0.998
16:68345675:T:C	W310R	0.998
16:68345689:G:C	W314C	0.998
16:68345689:G:T	W314C	0.998
16:68321444:G:A	M38I	0.997
16:68321444:G:C	M38I	0.997
16:68321444:G:T	M38I	0.997
16:68321451:G:C	D41H	0.997
16:68324692:T:G	Y48D	0.997
16:68324765:G:A	G72D	0.997
16:68324771:G:A	G74D	0.997
16:68329090:G:C	A103P	0.997
16:68337489:T:C	L141P	0.997
16:68337516:T:C	L150P	0.997
16:68339338:T:A	V174E	0.997

dbSNP variants (sampled 300 via entrez): RS1000124069 (16:68355015 A>C), RS1000154493 (16:68341084 G>A,C), RS1000160210 (16:68311550 C>T), RS1000234417 (16:68309252 G>A), RS1000240434 (16:68320182 G>A), RS1000307455 (16:68335673 T>A), RS1000365002 (16:68351903 A>G), RS1000385968 (16:68346917 C>T), RS1000453835 (16:68341625 T>C), RS1000561467 (16:68324290 A>G), RS1000573334 (16:68360194 G>A), RS1000578104 (16:68318741 C>T), RS1000697778 (16:68350628 C>A,T), RS1000729382 (16:68356188 T>C), RS1000734892 (16:68319141 G>C)

Disease associations

OMIM: gene MIM:610087 | disease phenotypes: MIM:617157, MIM:619191

GenCC curated gene-disease

Disease	Classification	Inheritance
short stature-brachydactyly-obesity-global developmental delay syndrome	Strong	Autosomal recessive

Mondo (9): short stature-brachydactyly-obesity-global developmental delay syndrome (MONDO:0014944), fatty liver disease (MONDO:0004790), acanthosis nigricans (MONDO:0007035), obesity disorder (MONDO:0011122), skeletal dysplasia (MONDO:0018230), renal hypoplasia (MONDO:0019637), brachydactyly (MONDO:0021004), hyperlipidemia (MONDO:0021187), epilepsy, progressive myoclonic, 12 (MONDO:0030936)

Orphanet (6): Short stature-brachydactyly-obesity-global developmental delay syndrome (Orphanet:464288), Primary bone dysplasia (Orphanet:364526), Obesity due to melanocortin 4 receptor deficiency (Orphanet:71529), Renal hypoplasia (Orphanet:93101), NON RARE IN EUROPE: Acanthosis nigricans (Orphanet:924), NON RARE IN EUROPE: Non rare obesity (Orphanet:521399)

HPO phenotypes

89 total (30 of 89 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000010	Recurrent urinary tract infections
HP:0000028	Cryptorchidism
HP:0000076	Vesicoureteral reflux
HP:0000089	Renal hypoplasia
HP:0000212	Gingival overgrowth
HP:0000218	High palate
HP:0000233	Thin vermilion border
HP:0000248	Brachycephaly
HP:0000252	Microcephaly
HP:0000272	Malar flattening
HP:0000278	Retrognathia
HP:0000286	Epicanthus
HP:0000316	Hypertelorism
HP:0000343	Long philtrum
HP:0000384	Preauricular skin tag
HP:0000407	Sensorineural hearing impairment
HP:0000431	Wide nasal bridge
HP:0000455	Broad nasal tip
HP:0000457	Depressed nasal ridge
HP:0000463	Anteverted nares
HP:0000470	Short neck
HP:0000483	Astigmatism
HP:0000486	Strabismus
HP:0000490	Deeply set eye
HP:0000508	Ptosis
HP:0000588	Optic disc coloboma
HP:0000589	Coloboma
HP:0000592	Blue sclerae
HP:0000620	Dacryocystitis

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST000756_2	Magnesium levels	2.000000e-06
GCST002783_278	Body mass index	4.000000e-07
GCST002783_633	Body mass index	1.000000e-06
GCST004904_185	Body mass index	3.000000e-08
GCST006249_87	Serum metabolite levels	6.000000e-11
GCST008152_39	Weight	4.000000e-07
GCST008362_60	Birth weight	7.000000e-06
GCST008362_61	Birth weight	1.000000e-08
GCST008363_126	Offspring birth weight	8.000000e-08
GCST008906_1	Schizophrenia	3.000000e-06
GCST010002_113	Refractive error	2.000000e-14
GCST012231_138	A body shape index	8.000000e-09
GCST012232_25	Lipoprotein (a) levels	3.000000e-12

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004845	magnesium measurement
EFO:0004340	body mass index
EFO:0004338	body weight
EFO:0004344	birth weight
EFO:0005939	parental genotype effect measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0006925	lipoprotein A measurement

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D000052	Acanthosis Nigricans	C17.800.621.430.530.100
D059327	Brachydactyly	C05.660.585.262; C16.131.621.585.262
D005234	Fatty Liver	C06.552.241
D006949	Hyperlipidemias	C18.452.584.500.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3562175 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,522 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1088977	ADEMETIONINE	3	1,522

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — 2.1.1.- Protein arginine N-methyltransferases

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
DS-437	Inhibition	5.22	pIC50

ChEMBL bioactivities

56 potent at pChembl≥5 of 68 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.40	IC50	0.4	nM	CHEMBL6103457
7.11	IC50	77	nM	CHEMBL5303356
6.96	IC50	110	nM	S-ADENOSYLHOMOCYSTEINE
6.66	IC50	220	nM	CHEMBL5206272
6.65	IC50	226	nM	CHEMBL5202088
6.53	IC50	294	nM	CHEMBL5562317
6.50	IC50	320	nM	CHEMBL5199380
6.50	Kd	320	nM	CHEMBL6132636
6.39	IC50	410	nM	CHEMBL5180108
6.31	IC50	491	nM	ADEMETIONINE
6.30	IC50	500	nM	CHEMBL6132636
6.27	IC50	540	nM	CHEMBL5408585
6.26	IC50	550	nM	CHEMBL5170047
6.26	IC50	555	nM	CHEMBL5613785
6.21	IC50	610	nM	CHEMBL6149781
6.20	IC50	631	nM	CHEMBL5186617
6.03	IC50	940	nM	CHEMBL6170788
6.00	IC50	1000	nM	CHEMBL538693
5.90	IC50	1270	nM	CHEMBL6149873
5.78	IC50	1680	nM	CHEMBL5173678
5.78	IC50	1670	nM	CHEMBL6172522
5.73	IC50	1850	nM	CHEMBL6142991
5.71	IC50	1960	nM	CHEMBL6166289
5.68	IC50	2100	nM	CHEMBL5561462
5.64	IC50	2300	nM	CHEMBL5563222
5.62	IC50	2400	nM	CHEMBL5560678
5.62	IC50	2400	nM	CHEMBL5613745
5.62	IC50	2400	nM	CHEMBL5094158
5.60	IC50	2500	nM	CHEMBL5527953
5.60	IC50	2500	nM	CHEMBL5185202
5.59	IC50	2550	nM	CHEMBL6133309
5.59	IC50	2580	nM	CHEMBL6143398
5.59	IC50	2570	nM	CHEMBL6171993
5.58	IC50	2630	nM	CHEMBL6168787
5.49	IC50	3230	nM	CHEMBL6173686
5.47	IC50	3410	nM	CHEMBL6150027
5.46	IC50	3440	nM	CHEMBL6169590
5.42	IC50	3810	nM	CHEMBL6145743
5.34	IC50	4560	nM	CHEMBL6142311
5.33	IC50	4680	nM	CHEMBL5191769
5.33	IC50	4710	nM	CHEMBL6151762
5.30	IC50	5000	nM	CHEMBL6134055
5.27	IC50	5370	nM	CHEMBL6144701
5.26	IC50	5490	nM	CHEMBL6168599
5.25	IC50	5600	nM	CHEMBL5396270
5.22	IC50	6000	nM	CHEMBL3577854
5.15	Kd	7120	nM	CHEMBL6134055
5.13	IC50	7490	nM	CHEMBL6171072
5.12	IC50	7500	nM	CHEMBL2169919
5.10	IC50	7980	nM	CHEMBL6152768

PubChem BioAssay actives

26 with measured affinity, of 143 total; 24 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-[4-[[4-(4-chlorophenyl)phenyl]methylamino]butylsulfanylmethyl]oxolane-3,4-diol	2074379: Inhibition of full-length PRMT7 (unknown origin) expressed in Sf9 cells using biotinylated H2B as substrate incubated for 60 mins in presence of 3H-SAM by Topcount plate reader analysis	ic50	0.0025	uM
(2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-[4-[[3-(4-chlorophenyl)phenyl]methylamino]butylsulfanylmethyl]oxolane-3,4-diol	1882377: Inhibition of PRMT7 (unknown origin)	ic50	0.0025	uM
(2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-[3-[(4-phenylphenyl)methylamino]propylsulfanylmethyl]oxolane-3,4-diol	2074379: Inhibition of full-length PRMT7 (unknown origin) expressed in Sf9 cells using biotinylated H2B as substrate incubated for 60 mins in presence of 3H-SAM by Topcount plate reader analysis	ic50	0.0025	uM
(2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid	1689511: Inhibition of recombinant human PRMT7 using GST-GAR as substrate by hotspot assay	ic50	0.1100	uM
methyl 6-[5-[[N’-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]carbamimidoyl]amino]pentylcarbamoylamino]-4-hydroxynaphthalene-2-carboxylate	1883074: Inhibition of human full length recombinant his-tagged PRMT7 (2 to 692 residues) using GST-GAR as substrate incubated for 20 mins in presence of [3H]-SAM by radioisotope-based filter assay	ic50	0.2200	uM
methyl 6-[4-[[amino-[2-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]ethylamino]methylidene]amino]butylcarbamoylamino]-4-hydroxynaphthalene-2-carboxylate	1883074: Inhibition of human full length recombinant his-tagged PRMT7 (2 to 692 residues) using GST-GAR as substrate incubated for 20 mins in presence of [3H]-SAM by radioisotope-based filter assay	ic50	0.2260	uM
methyl 6-[3-[[N’-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]carbamimidoyl]amino]propylcarbamoylamino]-4-hydroxynaphthalene-2-carboxylate	1883074: Inhibition of human full length recombinant his-tagged PRMT7 (2 to 692 residues) using GST-GAR as substrate incubated for 20 mins in presence of [3H]-SAM by radioisotope-based filter assay	ic50	0.3200	uM
methyl 7-[6-[[N’-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]carbamimidoyl]amino]hexylcarbamoylamino]-4-hydroxynaphthalene-2-carboxylate	1883074: Inhibition of human full length recombinant his-tagged PRMT7 (2 to 692 residues) using GST-GAR as substrate incubated for 20 mins in presence of [3H]-SAM by radioisotope-based filter assay	ic50	0.4100	uM
methyl 6-[2-[[N’-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]carbamimidoyl]amino]ethylcarbamoylamino]-4-hydroxynaphthalene-2-carboxylate	2012350: Inhibition of N-terminal/C-terminal His-tagged human recombinant full-length PRMT7 (2 to 692 residues) using histone GST-GAR as substrate and 3H-SAM as cosubstrate incubated for 60 mins by scintillation counter analysis	ic50	0.5400	uM
methyl 6-[4-[[N’-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]carbamimidoyl]amino]butylcarbamoylamino]-4-hydroxynaphthalene-2-carboxylate	1883074: Inhibition of human full length recombinant his-tagged PRMT7 (2 to 692 residues) using GST-GAR as substrate incubated for 20 mins in presence of [3H]-SAM by radioisotope-based filter assay	ic50	0.5500	uM
2-[2-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]ethyl]-1-(2-bromophenyl)guanidine	2127585: Inhibition of PRMT7 (unknown origin)	ic50	0.5550	uM
methyl 6-[7-[[N’-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]carbamimidoyl]amino]heptylcarbamoylamino]-4-hydroxynaphthalene-2-carboxylate	1883074: Inhibition of human full length recombinant his-tagged PRMT7 (2 to 692 residues) using GST-GAR as substrate incubated for 20 mins in presence of [3H]-SAM by radioisotope-based filter assay	ic50	0.6310	uM
(2S,3S,4R,5R)-2-(3-aminopropylsulfanylmethyl)-5-(6-aminopurin-9-yl)oxolane-3,4-diol	2074379: Inhibition of full-length PRMT7 (unknown origin) expressed in Sf9 cells using biotinylated H2B as substrate incubated for 60 mins in presence of 3H-SAM by Topcount plate reader analysis	ic50	1.0000	uM
methyl 6-[4-[[N’-[(E)-3-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]prop-2-enyl]carbamimidoyl]amino]butylcarbamoylamino]-4-hydroxynaphthalene-2-carboxylate	1883074: Inhibition of human full length recombinant his-tagged PRMT7 (2 to 692 residues) using GST-GAR as substrate incubated for 20 mins in presence of [3H]-SAM by radioisotope-based filter assay	ic50	1.6800	uM
7-N-[5-fluoro-2-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]-3-methylnaphthalene-1,7-diamine	2074382: Inhibition of PRMT7 (unknown origin)	ic50	2.1000	uM
7-N-[2-(1,3-benzodioxol-5-yl)-5-fluoropyrimidin-4-yl]-3-methylnaphthalene-1,7-diamine	2074382: Inhibition of PRMT7 (unknown origin)	ic50	2.3000	uM
7-N-[2-(1-benzofuran-2-yl)-5-fluoropyrimidin-4-yl]-3-methylnaphthalene-1,7-diamine	2074382: Inhibition of PRMT7 (unknown origin)	ic50	2.4000	uM
2-[2-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]ethyl]-1-phenylguanidine	2127552: Inhibition of human PRMT7 using GST-GAR as substrate and SAM as cofactor by radiometric HotSpot assay	ic50	2.4000	uM
7-N-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoropyrimidin-4-yl]-3-methylnaphthalene-1,7-diamine	2074382: Inhibition of PRMT7 (unknown origin)	ic50	2.5000	uM
methyl 6-[4-[[N’-[3-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]propyl]carbamimidoyl]amino]butylcarbamoylamino]-4-hydroxynaphthalene-2-carboxylate	1883074: Inhibition of human full length recombinant his-tagged PRMT7 (2 to 692 residues) using GST-GAR as substrate incubated for 20 mins in presence of [3H]-SAM by radioisotope-based filter assay	ic50	4.6800	uM
methyl 6-[3-[[N’-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]carbamimidoyl]amino]propylcarbamoylamino]-4-hydroxy-8-(trifluoromethyl)naphthalene-2-carboxylate	2012350: Inhibition of N-terminal/C-terminal His-tagged human recombinant full-length PRMT7 (2 to 692 residues) using histone GST-GAR as substrate and 3H-SAM as cosubstrate incubated for 60 mins by scintillation counter analysis	ic50	5.6000	uM
1-[2-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]ethyl]-3-ethylurea	1226186: Inhibition of human full length PRMT7 expressed in Sf9 cells assessed as inhibition of H2B[23-37] methylation	ic50	6.0000	uM
1-[3-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea	1226183: Inhibition of human full length PRMT7 expressed in Sf9 cells	ic50	7.5000	uM
(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]pentanoyl]amino]-5-[[N’-[3-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]propyl]carbamimidoyl]amino]pentanoic acid	2127552: Inhibition of human PRMT7 using GST-GAR as substrate and SAM as cofactor by radiometric HotSpot assay	ic50	8.3000	uM

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, decreases expression, increases expression	3
Ribavirin	decreases expression	2
pirinixic acid	affects binding, decreases expression, increases activity	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
jinfukang	increases expression	1
NSC 689534	affects binding, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Leflunomide	decreases expression	1
Atrazine	decreases expression	1
Berberine	increases expression	1
Copper	affects binding, decreases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, affects expression	1
Plant Extracts	affects cotreatment, increases expression	1
Progesterone	affects expression, affects cotreatment	1
S-Adenosylhomocysteine	decreases activity	1
Silicon Dioxide	decreases methylation	1
Tetrachlorodibenzodioxin	affects expression	1
Thiram	decreases expression	1
8-Bromo Cyclic Adenosine Monophosphate	decreases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	decreases expression	1
Copper Sulfate	decreases expression	1

ChEMBL screening assays

100 unique, capped per target: 98 binding, 2 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3578932	Binding	Inhibition of human full length PRMT7 expressed in Sf9 cells	Discovery of a Dual PRMT5-PRMT7 Inhibitor. — ACS Med Chem Lett
CHEMBL5445483	Functional	Affinity Phenotypic Cellular interaction: (HSP70 monomethylation in C2C12 cells) EUB0000236b PRMT7	Affinity Phenotypic Cellular Literature for EUbOPEN Chemogenomic Library

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B7YW	Abcam Raji PRMT7 KO	Cancer cell line	Male
CVCL_B9ZM	Abcam THP-1 PRMT7 KO	Cancer cell line	Male
CVCL_C7BB	Abcam PC-3 PRMT7 KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00160407	PHASE4	COMPLETED	Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
NCT00207311	PHASE4	COMPLETED	Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus
NCT00274495	PHASE4	TERMINATED	Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver
NCT00736385	PHASE4	TERMINATED	Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
NCT00742326	PHASE4	TERMINATED	Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
NCT01720719	PHASE4	UNKNOWN	Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
NCT01761318	PHASE4	COMPLETED	Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
NCT02102646	PHASE4	COMPLETED	MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
NCT02210715	PHASE4	COMPLETED	Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients
NCT02660047	PHASE4	COMPLETED	Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent
NCT02669641	PHASE4	UNKNOWN	Complex Imaging Assessment of Steatosis
NCT03374358	PHASE4	COMPLETED	Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
NCT03646292	PHASE4	COMPLETED	Antidiabetic Drugs for Steatotic Liver Disease
NCT03851627	PHASE4	RECRUITING	Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism
NCT05898841	PHASE4	COMPLETED	Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
NCT06989723	PHASE4	RECRUITING	Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
NCT02438020	PHASE4	UNKNOWN	Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity
NCT00076362	PHASE4	COMPLETED	Pediatric Hypothalamic Obesity
NCT00079547	PHASE4	COMPLETED	The Safety and Effectiveness of Low and High Carbohydrate Diets
NCT00115063	PHASE4	TERMINATED	LOSS- Louisiana Obese Subjects Study
NCT00134303	PHASE4	COMPLETED	Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
NCT00143936	PHASE4	COMPLETED	The Safety and Efficacy of Low and High Carbohydrate Diets
NCT00143962	PHASE4	COMPLETED	Comparison of Two Approaches to Weight Loss Follow-Up Study
NCT00152360	PHASE4	COMPLETED	The Effect of Xenical on Weight and Risk Factors
NCT00176306	PHASE4	COMPLETED	Levofloxacin Pharmacokinetics (PK) in the Severely Obese
NCT00203450	PHASE4	COMPLETED	Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial
NCT00205504	PHASE4	COMPLETED	Oral Contraceptives in the Metabolic Syndrome
NCT00229229	PHASE4	TERMINATED	Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease
NCT00234988	PHASE4	COMPLETED	A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
NCT00264589	PHASE4	COMPLETED	Exercise Training and Cardiovascular Function in Obesity and in Type 2 Diabetes
NCT00288873	PHASE4	COMPLETED	Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
NCT00298857	PHASE4	TERMINATED	A Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights
NCT00315146	PHASE4	COMPLETED	Optimizing Body Composition for Function in Older Adults
NCT00319202	PHASE4	TERMINATED	Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects
NCT00327912	PHASE4	UNKNOWN	Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal Switch for Superobesity
NCT00352287	PHASE4	COMPLETED	Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
NCT00353054	PHASE4	COMPLETED	Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.
NCT00390637	PHASE4	COMPLETED	Diet, Obesity and Genes (DiOGenes)
NCT00415688	PHASE4	COMPLETED	Lifestyle Modification for Obesity-Related Type 2 Diabetes
NCT00433641	PHASE4	COMPLETED	Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes